231 related articles for article (PubMed ID: 30215912)
1. Crisaborole (Eucrisa) for Mild to Moderate Atopic Dermatitis.
Castelli G; Schaffer M
Am Fam Physician; 2018 Sep; 98(6):379-380. PubMed ID: 30215912
[No Abstract] [Full Text] [Related]
2. Crisaborole 2% Ointment (Eucrisa
Gupta AK; Versteeg SG; Abramovits W; Vincent KD
Skinmed; 2017; 15(5):377-380. PubMed ID: 29139367
[No Abstract] [Full Text] [Related]
3. Crisaborole 2% Ointment for Mild-to-Moderate Atopic Dermatitis.
Riahi A; Lam JM
Skin Therapy Lett; 2021 Jan; 26(1):1-4. PubMed ID: 33539061
[TBL] [Abstract][Full Text] [Related]
4. Crisaborole: A new and effective nonsteroidal topical drug for atopic dermatitis.
Kailas A
Dermatol Ther; 2017 Sep; 30(5):. PubMed ID: 28834023
[No Abstract] [Full Text] [Related]
5. Crisaborole 2% Ointment (Eucrisa) for Atopic Dermatitis.
Woo TE; Kuzel P
Skin Therapy Lett; 2019 Mar; 24(2):4-6. PubMed ID: 30970204
[TBL] [Abstract][Full Text] [Related]
6. Topical Crisaborole in the Treatment of Atopic Hand Dermatitis: A Retrospective Chart Review.
Kahn JS; Grossman-Kranseler JS; Zancanaro P; Griffiths D; Dumont N; Rosmarin D
Dermatitis; 2021 Nov-Dec 01; 32(6):e141-e143. PubMed ID: 34570730
[No Abstract] [Full Text] [Related]
7. Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis.
Paton DM
Drugs Today (Barc); 2017 Apr; 53(4):239-245. PubMed ID: 28492291
[TBL] [Abstract][Full Text] [Related]
8. Crisaborole Ointment 2%: A Review in Mild to Moderate Atopic Dermatitis.
Hoy SM
Am J Clin Dermatol; 2017 Dec; 18(6):837-843. PubMed ID: 29076116
[TBL] [Abstract][Full Text] [Related]
9. A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents With Mild to Moderate Atopic Dermatitis.
Stein Gold LF; Spelman L; Spellman MC; Hughes MH; Zane LT
J Drugs Dermatol; 2015 Dec; 14(12):1394-9. PubMed ID: 26659931
[TBL] [Abstract][Full Text] [Related]
10. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2.
Clark R; Bozkaya D; Levenberg M; Faulkner S; Smith TW; Gerber RA
J Med Econ; 2018 Aug; 21(8):770-777. PubMed ID: 29706103
[TBL] [Abstract][Full Text] [Related]
11. Crisaborole Topical Ointment, 2% in Adults With Atopic Dermatitis: A Phase 2a, Vehicle-Controlled, Proof-of-Concept Study.
Murrell DF; Gebauer K; Spelman L; Zane LT
J Drugs Dermatol; 2015 Oct; 14(10):1108-12. PubMed ID: 26461821
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.
Paller AS; Tom WL; Lebwohl MG; Blumenthal RL; Boguniewicz M; Call RS; Eichenfield LF; Forsha DW; Rees WC; Simpson EL; Spellman MC; Stein Gold LF; Zaenglein AL; Hughes MH; Zane LT; Hebert AA
J Am Acad Dermatol; 2016 Sep; 75(3):494-503.e6. PubMed ID: 27417017
[TBL] [Abstract][Full Text] [Related]
13. Predictors of Systemic Exposure to Topical Crisaborole: A Nonlinear Regression Analysis.
Purohit V; Riley S; Tan H; Ports WC
J Clin Pharmacol; 2020 Oct; 60(10):1344-1354. PubMed ID: 32433779
[TBL] [Abstract][Full Text] [Related]
14. Topical Agents for the Treatment of Atopic Dermatitis.
Eichenfield LF; Luger T; Papp K; Silverberg JI; Sierka D; Zang C; Tallman AM; Zielinski MA; Ports WC
J Drugs Dermatol; 2020 Jan; 19(1):50-64. PubMed ID: 31985912
[TBL] [Abstract][Full Text] [Related]
15. Evaluating crisaborole as a treatment option for atopic dermatitis.
Ramachandran V; Cline A; Feldman SR; Strowd LC
Expert Opin Pharmacother; 2019 Jun; 20(9):1057-1063. PubMed ID: 31002539
[TBL] [Abstract][Full Text] [Related]
16. Meeting the challenge of atopic dermatitis from infancy to adulthood, introduction.
Eichenfield LF
Semin Cutan Med Surg; 2017 Mar; 36(2 Suppl 2):S35. PubMed ID: 28654707
[No Abstract] [Full Text] [Related]
17. Addressing the immunopathogenesis of atopic dermatitis: advances in topical and systemic treatment.
Eichenfield LF; Stein Gold LF
Semin Cutan Med Surg; 2017 Mar; 36(2 Suppl 2):S45-S48. PubMed ID: 28654711
[TBL] [Abstract][Full Text] [Related]
18. [New treatments for atopic dermatitis].
Bradley M; Wahlgren CF
Lakartidningen; 2017 Nov; 114():. PubMed ID: 29292944
[TBL] [Abstract][Full Text] [Related]
19. Crisaborole, Dupilumab, and Sarilumab.
Hussar DA; Lee YF
J Am Pharm Assoc (2003); 2017; 57(5):640-643. PubMed ID: 28882252
[No Abstract] [Full Text] [Related]
20. Biomarkers of response to topical crisaborole in patients with mild/moderate pediatric atopic dermatitis from minimally invasive tape strip transcriptome.
Fishbein AB; Mukherji J; Demczuk M; Buranosky B; Osborn J; Moreno C; LaRoche D; Paller AS; Lu KQ
J Am Acad Dermatol; 2024 Mar; 90(3):629-632. PubMed ID: 37924950
[No Abstract] [Full Text] [Related]
[Next] [New Search]
